PCPierre Cochat

Pierre Cochat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pierre Cochat has a total of 502 co-authors. Here are the top co-authors by number of shared publications:

  • Justine Bacchetta

    Paediatric Nephrology Rheumatology and Dermatology Unit, Hospices Civils de Lyon, INSERM1033 Research Unit, Lyon, France

    14 shared publications
  • Bruno Ranchin

    Service de Néphrologie et Rhumatologie Pédiatrique; Centre de référence des maladies rénales rares; Hôpital Femme Mère Enfant; Hospices Civils de Lyon; Bron; France

    12 shared publications
  • Daniel Floret

    Université Claude Bernard, Lyon 1, Domaine Rockefeller, avenue Rockefeller, Lyon 69008, France

    10 shared publications
  • Laurence Dubourg

    Centre de référence des maladies rénales rares Néphrogones, Hospices Civils de Lyon, Lyon, France

    9 shared publications
  • Jérôme Harambat

    Néphrologie pédiatrique, Hôpital des Enfants, CHU

    8 shared publications
  • Aurélia Liutkus

    Centre de référence des Maladies Rénales Rares , Hôpital Femme Mère Enfant et Université de Lyon

    7 shared publications

Latest Publications

  • Health technology assessment in France

    by Lionel Collet, Pierre Cochat

  • French evaluation of innovative health technologies: Early access and fundings

    by Capucine Serain, Sylvie Chevret, Yann Chambon, Vanessa Hernando, Françoise Lucet, Samuel Seksik, Hassan Serrier, Elodie Velzenberger Maquart, Pierre Cochat


  • Open Access

    Hyperoxaluries primitives et secondaires

    by Justine Bacchetta, Pierre Cochat

    Médecine/sciences (M/S), revue internationale dans le domaine de la recherche biologique, médicale et en santé

  • Hyperoxaluria

    by Bodo Beck, Pierre Cochat, Yaacov Frishberg


  • Jean-Pierre Guignard

    by Marie-Sophie Ghuysen, Pierre Cochat

  • Hyperoxaluria

    by Bodo Beck, Pierre Cochat, Yaacov Frishberg

  • Traitement par ARN interférent : exemple de l’hyperoxalurie primitive

    by Pierre Cochat, Anne-Laure Sellier-Leclerc, Aurélia Bertholet-Thomas, Justine Bacchetta

    Les hyperoxaluries primitives sont transmises sur le mode autosomique récessif ; il s’agit d’affections rares, engageant souvent le pronostic rénal et parfois le pronostic vital, notamment dans les formes à début précoce. Il existe trois types, répondant à des déficits enzymatiques distincts. Le type 1 représente 85 % des cas et résulte d’un déficit enzymatique (alanine-glyoxylate aminotransférase) au niveau des peroxysomes du foie, à l’origine d’une hyperoxalurie qui s’exprime initialement par des lithiases avec ou sans néphrocalcinose. Au fur et à mesure que la filtration glomérulaire diminue, une surcharge systémique apparaît et n’épargne aucun organe. Le traitement repose jusque-là sur la transplantation combinée hépatique et rénale, avec une mortalité et une morbidité non négligeables. L’introduction récente de traitements par ARN interférent ouvre de nouvelles perspectives. En bloquant une synthèse enzymatique (glycolate-oxydase ou lacticodéshydrogénase a) en amont du déficit qui provoque la maladie, l’oxalurie se normalise et la tolérance du produit (administré par voie injectable tous les 1 à 3 mois) est bonne. Cette stratégie va permettre d’éviter l’insuffisance rénale chez les patients traités précocement et d’éviter la transplantation hépatique chez ceux dont le diagnostic aura été fait à un stade avancé de l’insuffisance rénale. Primary hyperoxalurias are rare disease with autosomal recessive inheritance; they often lead to kidney failure and can lead to life-threatening conditions, especially in early onset forms. There are three types, responding to distinct enzyme deficits. Type 1 represents 85% of cases and results from an enzyme deficiency (alanine-glyoxylate aminotransferase) in the peroxisomes of the liver, causing hyperoxaluria leading to urolithiasis with or without nephrocalcinosis. As glomerular filtration decreases, a systemic overload appears and spares no organ. Treatment has hitherto been based on combined liver and kidney transplantation, with significant mortality and morbidity. The recent introduction of interfering RNA treatments opens up new perspectives. By blocking an enzymatic synthesis (glycolate oxidase or lacticodehydrogenase a) upstream of the deficit that causes the disease, oxaluria normalizes and the tolerance of the drug (administered by injection every 1 to 3 months) is good. This strategy will help prevent kidney failure in patients treated early and avoid liver transplantation in those who are diagnosed at an advanced stage of kidney failure.


  • Long-term outcomes of peritoneal dialysis started in infants below 6 months of age: An experience from two tertiary centres

    by Angélique Dachy, Justine Bacchetta, Anne-Laure Sellier-Leclerc, Aurélia Bertholet-Thomas, Delphine Demède, Pierre Cochat, François Nobili, Bruno Ranchin

    Little data are available for infants who started renal replacement therapy before 6 months of age. Because of extra-renal comorbidities and uncertain outcomes, whether renal replacement therapy in neonates is justified remains debatable. We performed a retrospective analysis of all patients who began chronic peritoneal dialysis below 6 months between 2007 and 2017 in two tertiary centres. Results are presented as median (min;max). Seventeen patients (10 boys) were included (8 prenatal diagnoses, 6 premies), with the following diagnoses: congenital anomalies of kidney and urinary tract (n=9), oxalosis (n=5), congenital nephrotic syndrome (n=2) and renal vein thrombosis (n=1). Five patients had associated comorbidities. At peritoneal dialysis initiation, age was 2.6 (0.1;5.9) months, height-standard deviation score (SDS) -1.3 (-5.7;1.6) and weight-SDS -1.4 (-3.6;0.6). Peritoneal dialysis duration was 12 (2;32) months, and at peritoneal dialysis discontinuation height-SDS was -1.0 (-4.3;0.7) weight-SDS -0.7 (-3.2;0.2), parathyroid hormone 123 (44;1540) ng/L, and hemoglobin 110 (73;174) g/L. During the first 6 months of peritoneal dialysis, the median time of hospitalisation stay was 69 (15;182) days. Ten patients presented a total of 27 peritonitis episodes. Reasons for peritoneal dialysis discontinuation were switch to hemodialysis (n=6), transplantation (n=6), recovery of renal function (n=2) and death (n=1). After a follow-up of 4.3 (1.7;10.3) years, 12 patients were transplanted, 2 patients were still on peritoneal dialysis, 2 patients were dialysis free with severe chronic kidney disease and 1 patient had died. Seven patients displayed neurodevelopmental delay, of whom five needed special schooling. We confirm that most infants starting peritoneal dialysis before 6 months of age will be successfully transplanted and will have a favourable growth outcome. Their quality of life will be impacted by recurrent hospitalisations and neurodevelopmental delay is frequent.


  • Adherence to cysteamine in nephropathic cystinosis: A unique electronic monitoring experience for a better understanding. A prospective cohort study: CrYSTobs

    by Segolene Gaillard, Laurent Roche, Sandrine Lemoine, Georges Deschênes, Denis Morin, Christine Vianey-Saban, Cécile Acquaviva-Bourdain, Bruno Ranchin, Justine Bacchetta, Behrouz Kassai, et al.

    Introduction In nephropathic cystinosis (NC), adherence to cysteamine remains challenging; poor adherence is worsening the disease progression with a decline of kidney function and increase of extrarenal morbidities. Our objective was to describe adherence to cysteamine in NC patients, using electronic monitoring systems. Methods Patients with confirmed NC, aged > 4 years and receiving oral cysteamine (short acting or delayed release formulation as standard of care) from 3 French reference centers, were included. Adherence to treatment was primarily assessed as the percentage of days with a good adherence score, adherence score rating from 0 (poor) to 2 (good). A descriptive analysis was performed after 1-year follow-up. Results Seventeen patients (10 girls, median age: 13.9 (5.4–33.0) years) were included. Median age at diagnosis was 17.0 (3.0–76.9) months and age at start of cysteamine was 21.0 (15.5–116.3) months. Median daily dose of cysteamine was 1.05 (0.55–1.63) g/m2/day. Over the year, the median percentage of days with a good adherence score was 80 (1–99)% decreasing to 68 (1–99)% in patients > 11 years old. The median of average number of hours covered by treatment in a day was 22.5 (6.1–23.9) versus 14.9 (9.2–20.5) hours for delayed release versus short acting cysteamine. Conclusion Our data are the first describing a rather good adherence to cysteamine, decreasing in adolescents and adults. We described a potential interest of the delayed release formulation. Our data highlight the need for a multidisciplinary approach including therapeutic education and individualized approaches in NC patients transitioning to adulthood. Graphical abstract


  • Open Access

    Neuropsychological and neuroanatomical phenotype in 17 patients with cystinosis

    by Aurore Curie, Nathalie Touil, Ségolène Gaillard, Damien Galanaud, Nicolas Leboucq, Georges Deschênes, Denis Morin, Fanny Abad, Jacques Luauté, Eurielle Bodenan, et al.

    Background: Cystinosis is a rare autosomal recessive disorder caused by intracellular cystine accumulation. Proximal tubulopathy (Fanconi syndrome) is one of the first signs, leading to end-stage renal disease between the age of 12 and 16. Other symptoms occur later and encompass endocrinopathies, distal myopathy and deterioration of the central nervous system. Treatment with cysteamine if started early can delay the progression of the disease. Little is known about the neurological impairment which occurs later. The goal of the present study was to find a possible neuroanatomical dysmorphic pattern that could help to explain the cognitive profile of cystinosis patients. We also performed a detailed review of the literature on neurocognitive complications associated with cystinosis.Methods: 17 patients (mean age = 17.6 years, [5.4–33.3]) with cystinosis were included in the study. Neuropsychological assessment was performed including intelligence (Intelligence Quotient (IQ) with Wechsler’s scale), memory (Children Memory Scale and Wechsler Memory Scale), visuo-spatial (Rey’s figure test) and visuo-perceptual skills assessments. Structural brain MRI (3 T) was also performed in 16 out of 17 patients, with high resolution 3D T1-weighted, 3D FLAIR and spectroscopy sequences.Results: Intellectual efficiency was normal in patients with cystinosis (mean Total IQ = 93). However the Perceptual Reasoning Index (mean = 87, [63–109]) was significantly lower than the Verbal Comprehension Index (mean = 100, [59–138],p = 0.003). Memory assessment showed no difference between visual and verbal memory. But the working memory was significantly impaired in comparison with the general memory skills (p = 0.003). Visuospatial skills assessment revealed copy and reproduction scores below the 50th percentile rank in more than 70% of the patients. Brain MRI showed cortical and sub-cortical cerebral atrophy, especially in the parieto-occipital region and FLAIR hypersignals in parietal, occipital and brain stem/cerebellum. Patients with atrophic brain had lower Total IQ scores compared to non-atrophic cystinosis patients.Conclusions: Patients with cystinosis have a specific neuropsychological and neuroanatomical profile. We suggest performing a systematic neuropsychological assessment in such children aiming at considering adequate management.